Company Growth (employees)
Eli Lilly was founded in 1876 and is headquartered in Indianapolis, US
Key People at Eli Lilly
John Lechleiter
Chairman, President, and CEO
David Ricks
President and Chief Executive Officer
Jan Lundberg
Executive Vice President
Alfonso Zulueta
Senior Vice President and President
Barton Peterson
Senior Vice President, Corporate Affairs and Communications
Derica Rice
Executive Vice President, Global Services, and Chief Financial Officer
Jeffrey Simmons
Senior Vice President
Melissa Barnes
Senior Vice President
Enrique Conterno
Senior Vice President
Maria Crowe
President, Manufacturing Operations
Michael Harrington
Senior Vice President and General Counsel
Stephen Fry
Senior Vice President, Human Resources and Diversity
Susan Mahony
Senior Vice President and President
Fionnuala Walsh
Senior Vice President
Eli Lilly Office Locations
Eli Lilly has offices in Indianapolis, Chuo Ward, Wien, Melrose Park and in 2 other locations
Indianapolis, US (HQ)
Lilly Corporate Center
Toronto, CA
3650 Danforth Ave
Windlesham, GB
Erl Wood Manor Sunninghill Road
Melrose Park, AU
112 Wharf Rd
Wien, AT
8 10 Kölblgasse
Chuo Ward, JP
Sannomiya Plaza Building 7 1 5 Isogami Dori Chuo Ku, Kobe
Eli Lilly Data and Metrics
Eli Lilly Financial Metrics
Eli Lilly's revenue was reported to be $21.2 b in FY, 2016 which is a 6% increase from the previous period.
USD
Revenue (FY, 2016) | 21.2 b |
Revenue growth (FY, 2015 - FY, 2016), % | 6% |
Gross profit (FY, 2016) | 15.6 b |
Gross profit margin (FY, 2016), % | 73% |
Net income (FY, 2016) | 2.7 b |
Market capitalization (21-Jul-2017) | 89.1 b |
Cash (31-Dec-2016) | 4.6 b |
EV | 92.9 b |
Eli Lilly's current market capitalization is $89.1 b.
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Revenue | 23.1 b | 19.6 b | 20 b | 21.2 b |
Revenue growth, % | (15%) | 2% | 6% | |
Cost of goods sold | 4.9 b | 4.9 b | 5 b | 5.7 b |
Gross profit | 18.2 b | 14.7 b | 14.9 b | 15.6 b |
Gross profit Margin, % | 79% | 75% | 75% | 73% |
Pre tax profit | 5.9 b | 3 b | 2.8 b | 3.4 b |
Net Income | 4.7 b | 2.4 b | 2.4 b | 2.7 b |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Cash | 3.8 b | 3.9 b | 3.7 b | 4.6 b |
Accounts Receivable | 588.4 m | 566.7 m | 558.6 m | 736.9 m |
Inventories | 2.9 b | 2.7 b | 3.4 b | 3.6 b |
Current Assets | 13.1 b | 12.2 b | 12.6 b | 15.1 b |
PP&E | 8 b | 8 b | 8.1 b | 8.3 b |
Goodwill | 1.8 b | 4 b | 4 b | |
Total Assets | 35.2 b | 37.2 b | 35.6 b | 38.8 b |
Accounts Payable | 1.1 b | 1.1 b | 1.3 b | 1.3 b |
Dividends Payable | 523.5 m | 530.3 m | 539 m | 548.1 m |
Total Debt | 4.2 b | 5.4 b | 8 b | 8.4 b |
Current Liabilities | 8.9 b | 11.2 b | 8.2 b | 11 b |
Common Stock | 698.5 m | 694.6 m | 691.3 m | |
Additional Paid-in Capital | 5.1 b | 5.3 b | 5.6 b | 5.6 b |
Retained Earnings | 17 b | 16.5 b | 16 b | 16 b |
Total Equity | 17.6 b | 15.4 b | 14.6 b | 14.1 b |
Debt to Equity Ratio | 0.2 x | 0.3 x | 0.5 x | 0.6 x |
Debt to Assets Ratio | 0.1 x | 0.1 x | 0.2 x | 0.2 x |
Financial Leverage | 2 x | 2.4 x | 2.4 x | 2.8 x |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Net Income | 4.7 b | 2.4 b | 2.4 b | 2.7 b |
Cash From Operating Activities | 5.7 b | 4.4 b | 2.8 b | 4.9 b |
Purchases of PP&E | (1 b) | (1.2 b) | (1.1 b) | (1 b) |
Cash From Investing Activities | (2.1 b) | (3.9 b) | 26.8 m | (3.1 b) |
Short-term Borrowings | 2.7 b | (2.7 b) | 1.3 b | |
Long-term Borrowings | (10.5 m) | (1 b) | (2 b) | (200 k) |
Dividends Paid | (2.1 b) | (2.1 b) | (2.1 b) | (2.2 b) |
Cash From Financing Activities | (3.8 b) | (75.1 m) | (2.9 b) | (559.8 m) |
| USD | Y, 2016 |
|---|---|
EV/CFO | 19.1 x |
Revenue/Employee | 511.3 k |
Debt/Equity | 0.6 x |
Debt/Assets | 0.2 x |
Financial Leverage | 2.8 x |
Eli Lilly Acquisitions / Subsidiaries
| Acquired Company | Date | Deal Size |
|---|---|---|
| CoLucid Pharmaceuticals | January 18, 2017 | $960 m |
| Novartis Animal Health | April 22, 2014 | $5.4 b |
| Avid Radiopharmaceuticals | November 08, 2010 | $800 m |
| Alnara Pharmaceuticals | July 02, 2010 | $280 m |
| Imclone Systems | October 06, 2008 | $6.5 b |
Eli Lilly Market Value History
Eli Lilly Median Salaries
Source: 117 public H-1B filings from Eli Lilly
